Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor Canagliflozin With Sitagliptin as a Reference Arm
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 16 Sep 2016 Results of pooled analysis of three RCTs and a real-world study presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 09 Apr 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met, according to results published in Diabetes Care.